What is it about?
This article provides evidence-based data from clinical trials focusing on efficacy, safety and tolerability of nintedanib for treatment of IPF
Photo by Robina Weermeijer on Unsplash
Why is it important?
This article includes the update data from post-marketing reports and real world practices. Role of nintedanib in fibrosing interstitial lung diseases is also briefly mentioned.
Read the Original
This page is a summary of: Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update, Expert Review of Respiratory Medicine, October 2019, Taylor & Francis, DOI: 10.1080/17476348.2019.1673733.
You can read the full text:
The following have contributed to this page